NewLimit Series C raises $435M led by Founders Fund as Armstrong-backed startup moves epigenetic therapies toward human ...

A team has identified an experimental molecule capable of "reprogramming" the brain's immune cells to restore part of their ...

HAYA Therapeutics Announces First Cohort Dosed in Phase 1 Trial of HTX-001, an Investigational Cellular Reprogramming Therapy ...

The field of partial reprogramming is transitioning from successful mouse studies to its first human clinical trials. At the heart of this experiment lies the discovery of Yamanaka factors, proteins ...

The Spanish scientist works at Altos Labs, a secretive US biotech company funded by billionaires seeking to eliminate the ...

By combining advanced cellular reprogramming with AI-driven protein design, the company aims to reverse biological ageing and tackle multiple diseases at once.

Mesenchymal drift may help explain how cells lose stable identity and acquire pro-fibrotic, inflammatory mesenchymal traits ...

For years, Silicon Valley treated ageing as a background fact of life rather than a technical problem. Wealth from the AI ...